WO2002053139A3 - Combinaison d'antagoniste de recepteur d'acide amine excitateur et d'agoniste 5-ht1f : methode de traitement de troubles neurologiques - Google Patents

Combinaison d'antagoniste de recepteur d'acide amine excitateur et d'agoniste 5-ht1f : methode de traitement de troubles neurologiques Download PDF

Info

Publication number
WO2002053139A3
WO2002053139A3 PCT/US2001/045863 US0145863W WO02053139A3 WO 2002053139 A3 WO2002053139 A3 WO 2002053139A3 US 0145863 W US0145863 W US 0145863W WO 02053139 A3 WO02053139 A3 WO 02053139A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonist
treatment
amino acid
excitatory amino
neurological disorders
Prior art date
Application number
PCT/US2001/045863
Other languages
English (en)
Other versions
WO2002053139A8 (fr
WO2002053139A2 (fr
Inventor
Kirk Willis Johnson
Original Assignee
Lilly Co Eli
Kirk Willis Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Kirk Willis Johnson filed Critical Lilly Co Eli
Priority to AU2002241565A priority Critical patent/AU2002241565A1/en
Publication of WO2002053139A2 publication Critical patent/WO2002053139A2/fr
Publication of WO2002053139A3 publication Critical patent/WO2002053139A3/fr
Publication of WO2002053139A8 publication Critical patent/WO2002053139A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement de trouble neurologique, en particulier de la migraine, qui consiste à administrer à un patient une quantité efficace d'un antagoniste de récepteur d'acide aminé excitateur combiné à un agoniste 5HT1f.
PCT/US2001/045863 2001-01-05 2001-12-20 Combinaison d'antagoniste de recepteur d'acide amine excitateur et d'agoniste 5-ht1f : methode de traitement de troubles neurologiques WO2002053139A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002241565A AU2002241565A1 (en) 2001-01-05 2001-12-20 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25992301P 2001-01-05 2001-01-05
US60/259,923 2001-01-05

Publications (3)

Publication Number Publication Date
WO2002053139A2 WO2002053139A2 (fr) 2002-07-11
WO2002053139A3 true WO2002053139A3 (fr) 2002-08-22
WO2002053139A8 WO2002053139A8 (fr) 2003-11-13

Family

ID=22987001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045863 WO2002053139A2 (fr) 2001-01-05 2001-12-20 Combinaison d'antagoniste de recepteur d'acide amine excitateur et d'agoniste 5-ht1f : methode de traitement de troubles neurologiques

Country Status (2)

Country Link
AU (1) AU2002241565A1 (fr)
WO (1) WO2002053139A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011316225B2 (en) 2010-10-15 2016-05-19 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
CN104411301B (zh) 2012-04-18 2018-02-06 康特拉医药公司 适于改善运动障碍治疗的口服药物配方
EP3481385A1 (fr) 2016-07-11 2019-05-15 Contera Pharma APS Système d'administration pulsatile de médicament pour le traitement de l'akinésie matinale

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721252A (en) * 1994-10-05 1998-02-24 Eli Lilly And Company 5HT1F agonists for the treatment of migraine
WO1998045270A1 (fr) * 1997-04-07 1998-10-15 Eli Lilly And Company Agents a action pharmacologique
WO2001001972A2 (fr) * 1999-07-06 2001-01-11 Eli Lilly And Company ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721252A (en) * 1994-10-05 1998-02-24 Eli Lilly And Company 5HT1F agonists for the treatment of migraine
WO1998045270A1 (fr) * 1997-04-07 1998-10-15 Eli Lilly And Company Agents a action pharmacologique
WO2001001972A2 (fr) * 1999-07-06 2001-01-11 Eli Lilly And Company ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE

Also Published As

Publication number Publication date
AU2002241565A1 (en) 2002-07-16
WO2002053139A8 (fr) 2003-11-13
WO2002053139A2 (fr) 2002-07-11

Similar Documents

Publication Publication Date Title
WO2003015713A3 (fr) Traitement de tumeurs gliales avec des antagonistes du glutamate
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
WO2002032374A3 (fr) Methodes de traitement de troubles induits par l'il-18
MXPA02001306A (es) Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
WO2005102338A8 (fr) Methode de traitement de la douleur neuropathique au moyen d'un antagoniste du recepteur crth2
EP0900568A3 (fr) Antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
WO2006018024A3 (fr) Compositions cosmetiques et pharmaceutiques contenant des inhibiteurs de l'eca et/ou des antagonistes des recepteurs de l'angiotensine ii
WO2003096983A3 (fr) Methode de traitement de troubles dyslipidemiques
EP1471909A4 (fr) Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
WO2002098370A3 (fr) Methodes d'administration/dosage d'antagonistes de cd2 pour la prevention et le traitement des maladies auto-immunes ou inflammatoires
WO2003054216A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
WO2004000354A3 (fr) Procede de traitement du syndrome de la lipodystrophie
WO2002015920A3 (fr) Traitement des maladies d'hyperproliferation
EP2543384A3 (fr) Traitement des conditions impliquant la démyélinisation
WO2004024150A3 (fr) Methodes de traitement de troubles associes aux recepteurs mglu (metabotropiques du glutamate), notamment la dependance et la depression
WO2004110380A3 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
AU2003296341A8 (en) System and method for treating Parkinson's Disease and other movement disorders
WO2007006732A8 (fr) Combinaison synergique pour traiter une douleur (agoniste du recepteur canabinoide et agoniste du recepteur opioide)
EP1108426A3 (fr) Utilisation d'agonistes des prostaglandines pour traiter les troubles de l'érection et l'impotence
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
WO2004064766A3 (fr) Methode de traitement d'etats pathologiques par administration de streptolysine o
WO2003015690A3 (fr) Methode de traitement de l'insomnie primaire
WO2002053139A8 (fr) Combinaison d'antagoniste de recepteur d'acide amine excitateur et d'agoniste 5-ht1f : methode de traitement de troubles neurologiques
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 28/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 28/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP